VKTX Insider Trading

Insider Ownership Percentage: 4.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $84,832,228.79

Viking Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Viking Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$13MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Viking Therapeutics Share Price & Price History

Current Price: $25.65
Price Change: Price Decrease of -0.48 (-1.84%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for VKTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$25.65Closing price on 03/28/25:

SEC Filings (Institutional Ownership Changes) for Viking Therapeutics (NASDAQ:VKTX)

76.03% of Viking Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VKTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$224Mbought$173MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Viking Therapeutics logo
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Read More on Viking Therapeutics

Today's Range

Now: $25.65
Low: $25.21
High: $26.23

50 Day Range

MA: $30.29
Low: $25.65
High: $34.94

52 Week Range

Now: $25.65
Low: $24.41
High: $82.00

Volume

1,972,955 shs

Average Volume

3,896,595 shs

Market Capitalization

$2.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Who are the company insiders with the largest holdings of Viking Therapeutics?

Viking Therapeutics' top insider shareholders include:
  1. Brian Lian (CEO)
  2. Marianna Mancini (COO)
  3. Greg Zante (CFO)
  4. Lawson Macartney (Director)
  5. Charles A Rowland Jr (Director)
  6. J Matthew Singleton (Director)
  7. Sarah Kathryn Rouan (Director)
Learn More about top insider investors at Viking Therapeutics.

Who are the major institutional investors of Viking Therapeutics?

Viking Therapeutics' top institutional investors include:
  1. FMR LLC — 15.00%
  2. Vanguard Group Inc. — 9.13%
  3. Geode Capital Management LLC — 1.69%
  4. Susquehanna International Group LLP — 0.00%
  5. Braidwell LP — 1.33%
  6. Ameriprise Financial Inc. — 1.33%
Learn More about top institutional investors of Viking Therapeutics stock.

Which major investors are selling Viking Therapeutics stock?

In the previous quarter, VKTX stock was sold by these institutional investors:
  1. Citadel Advisors LLC
  2. International Assets Investment Management LLC
  3. Hood River Capital Management LLC
  4. Artia Global Partners LP
  5. Fred Alger Management LLC
  6. Emerald Advisers LLC
  7. Voya Investment Management LLC
  8. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.
Within the last year, company insiders that have sold Viking Therapeutics company stock include:
  1. Brian Lian (CEO)
  2. Marianna Mancini (COO)
  3. Greg Zante (CFO)
  4. Lawson Macartney (Director)
  5. Charles A Rowland Jr (Director)
  6. J Matthew Singleton (Director)
Learn More investors selling Viking Therapeutics stock.

Which major investors are buying Viking Therapeutics stock?

Within the previous quarter, VKTX stock was purchased by institutional investors including:
  1. Norges Bank
  2. Massachusetts Financial Services Co. MA
  3. Ameriprise Financial Inc.
  4. Raymond James Financial Inc.
  5. Raymond James Financial Inc.
  6. Man Group plc
  7. Braidwell LP
  8. Parallax Volatility Advisers L.P.